Comparative Analysis of Comprehensive Genomic Profile in Thymomas and Recurrent Thymomas Reveals Potentially Actionable Mutations for Target Therapies DOI Open Access
Filippo Lococo, Elisa De Paolis,

Jessica Evangelista

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(17), P. 9560 - 9560

Published: Sept. 3, 2024

Molecular profiles of thymomas and recurrent are far from being defined. Herein, we report an analysis a comprehensive genetic profile (CGP) in highly selected cohort thymomas. Among 426 thymomas, the tissue was available 23 tumors for matching biomolecular results obtained primary relapse samples. A control group composed non-recurrent thymoma patients through propensity score match analysis. CGP performed using NGS Tru-SightOncology assay to evaluate TMB, MSI, molecular alterations 523 genes. does not differ when comparing initial tumor with relapse. significantly higher frequency cell cycle genes (100.0% vs. 57.1%, p = 0.022) is detected early recurrence (<32 months) compared late cases. The CGPs were similar Finally, based on results, off-label treatment or clinical trial could be potentially proposed >50% cases (oncogenic Tier-IIC variants). In conclusion, do substantially between Cell gene associated after thymectomy. Multiple target therapies by performing CGP, suggesting that precision medicine approach these further explored.

Language: Английский

Unveiling the Link Between Chronic Inflammation and Cancer DOI Creative Commons

Siddhant Tripathi,

Yashika Sharma, Dileep Kumar

et al.

Metabolism Open, Journal Year: 2025, Volume and Issue: 25, P. 100347 - 100347

Published: Jan. 9, 2025

The highly nuanced transition from an inflammatory process to tumorigenesis is of great scientific interest. While it well known that environmental stimuli can cause inflammation, less about the oncogenic modifications chronic inflammation in tissue microenvironment bring about, as how these set off pro-tumorigenic processes. It clear no matter where factors come from, maintaining encourages carcinogenesis. In addition encouraging angiogenesis and metastatic processes, sustaining survival proliferation malignant transformed cells, possibly altering efficacy therapeutic agents, negatively regulate antitumoral adaptive innate immune responses. Because has multiple pathways involved metastasis, gained recognition a marker cancer desirable target for therapy. Recent advances our knowledge molecular mechanisms drive cancer's progression demonstrate promotes metastasis while suppressing anti-tumor immunity. many solid tumor types, including breast, lung, liver cancer, stimulates activation oncogenes impairs body's defenses against tumor. Additionally, alters As tactical approach treatment, findings have underscored importance targeting pathways. This review highlights role development focusing on its impact progression, suppression, therapy resistance. examines current anti-inflammatory strategies, NSAIDs, cytokine modulators, STAT3 inhibitors, addressing their potential limitations. emphasizes need further research unravel complex linking identify targets specific subtypes.

Language: Английский

Citations

4
The colorectal cancer microenvironment governs clinical behaviors and chemotherapy response DOI
André Holdfeldt, Simona Salerno, Anders Ståhlberg

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217687 - 217687

Published: April 1, 2025

Language: Английский

Citations

1
Enhancing detection and monitoring of circulating tumor cells: Integrative approaches in liquid biopsy advances DOI Creative Commons

Thanmayi Velpula,

Buddolla Viswanath

The Journal of Liquid Biopsy, Journal Year: 2025, Volume and Issue: 8, P. 100297 - 100297

Published: April 29, 2025

Language: Английский

Citations

0
Comparative Analysis of Comprehensive Genomic Profile in Thymomas and Recurrent Thymomas Reveals Potentially Actionable Mutations for Target Therapies DOI Open Access
Filippo Lococo, Elisa De Paolis,

Jessica Evangelista

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(17), P. 9560 - 9560

Published: Sept. 3, 2024

Molecular profiles of thymomas and recurrent are far from being defined. Herein, we report an analysis a comprehensive genetic profile (CGP) in highly selected cohort thymomas. Among 426 thymomas, the tissue was available 23 tumors for matching biomolecular results obtained primary relapse samples. A control group composed non-recurrent thymoma patients through propensity score match analysis. CGP performed using NGS Tru-SightOncology assay to evaluate TMB, MSI, molecular alterations 523 genes. does not differ when comparing initial tumor with relapse. significantly higher frequency cell cycle genes (100.0% vs. 57.1%, p = 0.022) is detected early recurrence (<32 months) compared late cases. The CGPs were similar Finally, based on results, off-label treatment or clinical trial could be potentially proposed >50% cases (oncogenic Tier-IIC variants). In conclusion, do substantially between Cell gene associated after thymectomy. Multiple target therapies by performing CGP, suggesting that precision medicine approach these further explored.

Language: Английский

Citations

0